LEGEND BIOTECH CORP. news, videos and press releases
For more news please use our advanced search feature.
LEGEND BIOTECH CORP. - More news...
LEGEND BIOTECH CORP. - More news...
- Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
- Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
- Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
- Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
- Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
- Legend Biotech Appoints Alan Bash as President of CARVYKTI®
- Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
- Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
- Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
- Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
- Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
- Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
- Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
